Skip to content
value.today

THAR Pharmaceuticals Inc.

🇺🇸 Pittsburgh, Pennsylvania, USAPharmaceuticalsFounded 2008
Total raised
$12 M
4 rounds on record
Latest round
$1 M
Aug 2014
First round on record
Nov 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of THAR Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2014$1 MNo. 4Under $2 million

THAR Pharmaceuticals Inc.: Raise no. 4, Aug 2014

Investors in this round

18 investors had bought by the notice of Apr 5, 2016: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$350,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian K. Moyer · Executive Officer · Vice President, Corporate Development & Finance
  • Ira K. Kalfus · Executive Officer · Chief Medical Officer of Issuer
  • Jason K. Bablak · Executive Officer · Vice President, Regulatory Affairs
  • Mazen K. Hanna · Executive Officer · Chief Scientific Officer
  • Raymond K. Houck · Executive Officer, Director · President, Chief Executive Officer and Director of Issuer
  • Lalit K. Chordia · Director
  • Philip K. Sussman · Director
  • Robert K. Roy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A use of proceeds is working capital, which use includes salaries of executive officers.”

Signed by Raymond K. Houck, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 5, 2016. Read the notice at the SEC.

debt, optionsSEC
Nov 2012$4 MNo. 3$2 to $10 million

THAR Pharmaceuticals Inc.: Raise no. 3, Nov 2012

Investors in this round

32 investors had bought by the notice of Nov 12, 2013: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$800,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Moyer · Executive Officer
  • Jason Bablak · Executive Officer
  • Mazen Hanna · Executive Officer
  • Raymond Houck · Executive Officer, Director
  • Filip Amram · Director
  • Lalit Chordia · Director
  • Philip Sussman · Director
  • Robert Roy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A use of proceeds is working capital, which use includes salaries of executive officers.”

Signed by Brian Moyer, Vice President, Corporate Development. Source: SEC Form D, newest notice filed Nov 12, 2013. Read the notice at the SEC.

debt, optionsSEC
Oct 2011$2 MNo. 2Under $2 million

THAR Pharmaceuticals Inc.: Raise no. 2, Oct 2011

Investors in this round

21 investors had bought by the notice of Apr 19, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$450,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Moyer · Executive Officer
  • Jason Bablak · Executive Officer
  • Mazen Hanna · Executive Officer
  • Raymond Houck · Executive Officer, Director
  • Filip Amram · Director
  • Lalit Chordia · Director
  • Philip Sussman · Director
  • Robert Roy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A use of proceeds is working capital, which use includes salaries of executive officers.”

Signed by Brian Moyer, Vice President, Corporate Development. Source: SEC Form D, newest notice filed Apr 19, 2013. Read the notice at the SEC.

debt, optionsSEC
Nov 2010$4 MNo. 1$2 to $10 million

THAR Pharmaceuticals Inc.: Raise no. 1, Nov 2010

Investors in this round

5 investors had bought by the notice of Jan 3, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $10 M offered; $5 M still to sell
Smallest investment taken
$100,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$796,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Moyer · Executive Officer
  • Jason Bablak · Executive Officer
  • Mazen Hanna · Executive Officer, Director
  • Raymond Houck · Executive Officer, Director
  • Filip Amram · Director
  • Lalit Chordia · Director
  • Philip Sussman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount includes shares attributable to the sale of Series A-1 stock and warrants and the conversion of existing convertible debt. The final amount is subject to actual debt converted into shares and warrants exercised.”
  • On the use of proceeds: “A use of proceeds is working capital, which use includes salaries of executive officers.”

Signed by Brian Moyer, Vice President, Corporate Development. Source: SEC Form D and 1 amendment, newest notice filed Jan 3, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • THAR Pharmaceuticals Inc. had no revenue when it filed its newest notice of a funding round (Apr 2016).

    SEC Form D (revenue range) · Apr 2016

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2016

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of THAR Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 32 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by THAR Pharmaceuticals Inc.
NameRoleNamed in
Brian K. MoyerVice President, Corporate Development & FinanceApr 2016
Ira K. KalfusChief Medical Officer of IssuerApr 2016
Jason K. BablakVice President, Regulatory AffairsApr 2016
Mazen K. HannaChief Scientific OfficerApr 2016
Raymond K. HouckPresident, Chief Executive Officer and Director of IssuerApr 2016
Brian MoyerExecutive officerNov 2013
Jason BablakExecutive officerNov 2013
Mazen HannaExecutive officerNov 2013
Raymond HouckExecutive officerNov 2013
Lalit K. ChordiaDirectorApr 2016
Philip K. SussmanDirectorApr 2016
Raymond K. HouckPresident, Chief Executive Officer and Director of IssuerApr 2016
Robert K. RoyDirectorApr 2016
Filip AmramDirectorNov 2013
Lalit ChordiaDirectorNov 2013
Philip SussmanDirectorNov 2013
Raymond HouckDirectorNov 2013
Robert RoyDirectorNov 2013
Mazen HannaDirectorJan 2011